Cornea

The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

From amniotic membrane grafting to neurotization.

Plasma emission for blepharitis, meibomian gland dysfunction, and dry eye disease.

In this PER On Air Ophthalmology Times podcast, a team of experts provides insights into the diagnosis and management of patients with NK (including assessing their underlying cause of NK), with a look at the range of treatments available for patients with advanced stages of NK.

Phase 1 multicenter study demonstrates early signs of efficacy.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

Researchers found that blocking the interaction between peptide and receptor using topical applications of naltrexone reverses dry eye symptoms in 5 days and restores tear fluid volumes to normal baseline.

Two randomized, double-masked, placebo-controlled, Phase 3 trials named REVEAL-1 and REVEAL-2 are expected to start in August 2024.

According to the company, the treatment option can save time in the operating room and make the most of corneal donations.

The high-level analysis found that 82% of TEPEZZA-treated patients in the follow-up did not report needing any additional TED treatment for nearly 2 years.

Roy Rubinfeld, MD, MA, discussed EpiSmart cross-linking for keratoconus and the ongoing trials and results at the IKA 2024 Symposium.

At the IKA 2024 Symposium, Michael Belin, MD, discussed the ABCD Progression Display he developed to classify disease severity and help diagnose keratoconus earlier.

Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus at the IKA 2024 Symposium.

Melissa Barnett, OD, Director of Optometry at the University of California, Davis, talked about her session at IKA that focused on keratoconus from the patient perspective.

Elizabeth Yeu, MD, Executive Board Member of IKA, and a cataract and refractive surgeon at Virginia Eye Consultants, talked about perioperative considerations for cataract surgery in keratoconus patients.

Justin Schweitzer, OD, FAAO, from Vance Thompson Vision, talked about his session at the IKA Symposium discussing cross-linking in keratoconus treatment, with a look at both the present and looking toward the future.

Barry Eiden, OD, FAAO, FSLS, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus, the importance of early diagnosis, and the impact this can have on practices.

Christine Sindt, OD, FAAO, Clinical Professor of Ophthalmology and Visual Sciences at the University of Iowa School of Medicine, talked about her session at the meeting focusing on higher order aberrations and the correction of complicated optics on scleral contact lenses.

Alan Glazier, OD, FAAO, talked about a session he is a moderator in that discusses the education of the public on keratoconus, from screening to diagnosis, and the roles clinicians can take to assist in the anxieties of the patients.

Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus.

Alternate methods of screening may lead to earlier diagnosis of disease.

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

A singular celebration of science over the decades

Elias Kahan, MD, speaks about wide-field contact specular microscopy and the expanding scope of corneal endothelial research.